Bullous Keratopathy Market Value to reach US$ 650 Million by 2033, at a CAGR 4.3%

The global bullous keratopathy market is expected to register a CAGR of 4.3% from 2023 to 2033, reaching a valuation of US$ 427.54 Million in 2023, as per a recently published Future Market Insights report. For the assessment period of 2023 to 2033, a CAGR of 4.3% is expected, with a closing value of US$ 650 million. The rising prevalence of ophthalmic diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the key factor propelling the industry’s growth. According to the NCBI report, approximately 10-15% of patients diagnosed with keratoconus require to undergo a corneal implant procedure at some point.

A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16131

Corneal blindness is the third-leading cause of blindness after glaucoma and cataract affecting 10 million people globally. The most common cause of damage to endothelium layer of the cornea is eye surgery. Any kind of trauma, glaucoma, or inflammation from eye surgery can result in bullous keratopathy. Bullous keratopathy may occur in around 1% to 2% of patients undergoing cataract surgery, a nonsignificant number when you consider that approximately 10 million patients undergo cataract surgery worldwide each year.

Collagen-based bio-engineered artificial corneas used in Bullous Keratopathy have high demand in the market owing to their advantages, such as low cost, biocompatibility, and improved safety and effectiveness. There has been an increased focus of manufacturers to develop and launch new products. Currently, two products are in clinical trials and are expected to help the artificial cornea segment and overall industry growth over the forecast period. For instance, in 2022, Corneat Vision announced that its CorNeat KPro (artificial cornea) is undergoing clinical trials. This product is expected to receive marketing approval in 2024 which will aid in the market expansion of Bullous Keratopathy.

Corneal transplantation is the decisive treatment for Bullous Keratopathy as it revives the normal structure and function of endothelial cells. It can be done in the form of penetrating keratoplasty (PK), Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping automated endothelial keratoplasty (DSAEK). A cross-sectional national survey was conducted in Japan for 963 eyes with bullous keratopathy between 1999 and 2001 by members of the Japan Cornea Society. Demographic characteristics, type of surgery, complications, and postoperative outcomes were analyzed. Bullous keratopathy accounted for 24.2% (963 eyes) of total keratoplasties performed during the period (Shimazaki et al., 2007).

Contact Us for a Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16131

Key Takeaways from the Market Study

• Global bullous keratopathy market likely to reach US$ 650 Million by 2033
• North America is expected to hold highest market share during the forecast period.
• Europe Bullous keratopathy market accounted for a 19.1% business share in 2022.
• The amniotic membrane transplantation is an effective method of treatment for bullous keratopathy and has beneficial influence on the process of corneal healing and the improvement of visual acuity and diminish subjective symptoms.
• By end-user, hospital segment dominated the market with revenue share of US$ 150 Million.

“With major breakthroughs in ophthalmology becoming evident, the scope for bullous keratopathy is expected to rise significantly. Moreover, healthcare practitioners are gravitating towards more precise surgeries to improve patient outcomes,” remarks an analyst at FMI.

Competitive Landscape

Key players in the Bullous Keratopathy market are- Hoffmann-La Roche Ltd, Regeneron, Pharmaceuticals, Inc., Pfizer, Inc., Bayer AG, Cellusion, CRSTEurope, Barraquer Eye Hospital, Planchard Eye & Laser Center, Medscape. Some recent developments in bullous Keratopathy market are:

• In September 2022: Celregen and Cellusion Inc. signed an exclusive license agreement for corneal endothelial cell regenerative therapy in Greater China.
• In July 2022: Carl Zeiss Meditec and Precise Bio announced a partnership in the development and commercialization of tissue-based implants for ophthalmology

More Valuable Insights 

Future Market Insights, in its new offering, presents an unbiased analysis of the global Embolization Coils market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022 to 2032.

Visit for Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-16131

Key Segments Profiled in the Bullous Keratopathy Market Industry Survey

Bullous Keratopathy Market by Therapies:

• Emmecell
  • Drug Description
  • Regulatory Milestones
  • Safety and Efficiency
  • Product Profile
• Cellusion
  • Drug Description
  • Other Development Activities
  • Clinical Development
  • Safety and Efficiency
  • Product Profile

Bullous Keratopathy Market by End User:

• Hospitals
• Surgical Centers

Bullous Keratopathy Market by Treatment:

• Medical Management
  • Lubricants
  • Steroids
  • Hyperosmotic agents
  • Anti- Glaucoma drugs
  • Antibiotics
  • Amniotic Membrane Grafting (AMG)
  • Annular Keratotomy
  • Anterior Stromal Puncture

About the Healthcare at Future Market Insights 

The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs